Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibuzatrelvir in Non-Hospitalized Symptomatic Adult and Adolescent Participants With COVID-19 at High Risk of Severe Illness
NCT06679140Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Dec 2024
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of ibuzatrelvir in coronavirus disease 2019 (COVID-19), sponsored by Pfizer. Started Dec 2024; status: recruiting.
02
Drugs
ibuzatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06679140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06679140.